No difference seen in ongoing pregnancy versus hospital-controlled ovulation monitoring<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Sept. 14, 2023 (HealthDay News) — Home-based monitoring of ovulation is noninferior to hospital-controlled monitoring to time frozen-thawed embryo transfer (FET) for pregnancy, according to a study published online Sept. 4 in The Lancet<\/em>.<\/p>\n Tjitske Zaat, M.D., from the University of Amsterdam, and colleagues compared ongoing pregnancy rates after home-based monitoring versus hospital-controlled monitoring with ovulation triggering. The analysis included 1,464 women (aged 18 to 44 years) with a regular ovulatory menstrual cycle who were randomly assigned (1:1) to home-based monitoring or hospital-controlled monitoring.<\/p>\n The researchers found that ongoing pregnancy occurred in 20.8 percent of individuals in the home-based monitoring group and in 20.9 percent in the hospital-controlled monitoring group (risk ratio [RR], 0.99; 90 percent confidence interval [CI], 0.81 to 1.22; risk difference [RD], \u00e2\u0080\u00930.14; 90 percent CI, \u00e2\u0080\u00933.63 to 3.36). Predetermined noninferiority was achieved (RR, 1.00; 90 percent CI, 0.81 to 1.23; RD, \u00e2\u0080\u00930.08; 90 percent CI, \u00e2\u0080\u00933.60 to 3.44).<\/p>\n “Monitoring ovulation at home means a hospital visit once for the placement of these embryos instead of three to four times for hospital monitoring,” Zaat said in a statement. “This is more sustainable and reduces the cost of treatment by up to 80 percent.”<\/p>\n Several authors disclosed ties to the pharmaceutical industry.<\/p>\n <\/span>Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n